Pfizer, BioNTech Data Shows Covid-19 Vaccine Effective in Young Teens
22 November 2021 - 11:29PM
Dow Jones News
By Matt Grossman
Pfizer Inc. and BioNTech SE's Covid-19 vaccine showed strong
safety and efficacy in children aged 12 to 15 in a Phase 3 trial of
its use among that cohort, the companies said Monday.
Data from the trial showed that the vaccine was 100% effective
against Covid-19 from seven days after the second dose through more
than four months after the second dose, the companies said. There
were no serious safety concerns observed in people over six months
of safety follow-up, Pfizer and BioNTech said.
The data will be the basis for a regulatory submission seeking
full approval for the vaccine in people aged 12 to 15. The vaccine
is now available to people that age in the U.S. via an
emergency-use authorization from the Food and Drug
Administration.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
November 22, 2021 07:14 ET (12:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024